Life Sciences & Biotech Insurance in Ontario, Canada

Healthcare & Professional Insurance | Boardwalk Insurance — A Division of Oracle RMS

Life sciences and biotech insurance is a specialized commercial insurance program for pharmaceutical companies, biotechnology firms, medical device manufacturers, clinical research organizations (CROs), contract development and manufacturing organizations (CDMOs), and genomics and diagnostics companies operating in Canada. Life sciences companies face a layered risk profile that combines product liability for marketed products, clinical trial liability for human research subjects, professional liability for scientific and regulatory services, cyber liability for proprietary research data and patient information, and D&O for governance in a heavily regulated and investor-watched sector. Boardwalk Insurance serves Ontario life sciences and biotech firms from 30+ A-rated carriers. Serving all provinces except Quebec.

Get a Free Quote | Book a Meeting

5/5 Rating — 69+ Reviews | 15+ Years Experience | Dedicated Claims Support

What Is Life Sciences & Biotech Insurance?

Life sciences and biotech insurance is not a single policy — it is a coordinated insurance program addressing the distinct risk categories of companies that discover, develop, manufacture, and commercialize health-related products and services. At different stages of a life sciences company's development, different risks dominate: early-stage biotech companies face research liability and D&O exposure; clinical-stage companies face clinical trial liability and regulatory risk; commercial-stage companies face product liability for marketed products. A well-structured life sciences insurance program evolves with the company's development stage.

The Development Stage Insurance Framework

Pre-Clinical Stage (Research Companies) - D&O for investor governance - CGL for laboratory operations and premises - Professional Liability for scientific consulting and advisory services - Cyber Liability for proprietary research data and IP protection

Clinical Stage (IND/CTA Filed, Human Trials Active) - All of the above, plus: - Clinical Trials Liability — the most critical and most specialized coverage at this stage - Professional Liability expanded for regulatory and medical affairs services

Commercial Stage (Health Canada Approval, Product on Market) - All of the above, plus: - Product Liability — now the dominant risk - Product Recall coverage - Commercial auto for sales and distribution

Who Needs Life Sciences & Biotech Insurance in Ontario?

Pharmaceutical Companies

Canadian pharmaceutical companies — both domestic manufacturers and distributors of imported product — face product liability for the drugs they bring to market, professional liability for regulatory affairs and pharmacovigilance services, and commercial property exposure for manufacturing facilities with controlled substance inventories and cold-chain storage requirements.

Biotechnology Companies

Biotech companies developing novel therapies — monoclonal antibodies, cell and gene therapies, RNA therapeutics, and biologics — face product liability as products advance toward commercialization, clinical trials liability during human studies, and intellectual property exposure for their core technology platforms. The long development timelines and capital-intensive nature of biotech development create significant D&O exposure as investors monitor progress against milestones.

Medical Device Manufacturers

Medical device companies face product liability under Canada's Medical Devices Regulations under the Food and Drugs Act. The liability profile of a medical device company depends heavily on the device class — Class I devices (low risk) carry modest exposure, while Class III and Class IV implantable devices carry the highest product liability exposure in the industry. Defective implants, misdiagnosis from inaccurate diagnostic devices, and software-related device failures can generate multi-party claims involving the manufacturer, the implanting physician, and the hospital.

Clinical Research Organizations (CROs)

CROs that conduct clinical trials on behalf of sponsor companies — managing study sites, patient recruitment, data collection, and regulatory submissions — carry professional liability for trial management quality, clinical trials liability for adverse events in trial participants, and data integrity liability for the accuracy and completeness of trial data submitted to regulators. A CRO's error in trial management can compromise a sponsor's regulatory submission, generating significant professional negligence claims.

Contract Development and Manufacturing Organizations (CDMOs)

CDMOs that develop formulations, manufacture clinical trial materials, or produce commercial pharmaceutical and biologic products carry product liability for the products they manufacture, professional liability for development services, and commercial property exposure for GMP (Good Manufacturing Practice) facilities with specialized production infrastructure.

Diagnostics and Genomics Companies

Diagnostic testing companies and genomic analysis firms face professional liability for the accuracy of test results and genomic interpretations, product liability for in vitro diagnostic devices, and cyber liability for the highly sensitive genetic and health data they handle. The sensitivity of genomic data — which can affect not only the tested individual but their biological relatives — creates privacy liability that exceeds most other data categories.

What Does Life Sciences & Biotech Insurance Cover?

Clinical Trials Liability

Clinical trials liability is the most specialized and most critical insurance coverage for life sciences companies with active human research programs. It covers claims by clinical trial participants — study subjects enrolled in clinical trials — who experience adverse events or injuries that they attribute to the investigational product, the study procedures, or the trial's management.

Canadian clinical trials operate under Health Canada's Food and Drug Regulations and the ICH-E6 GCP guidelines. Research Ethics Boards (REBs) that approve clinical trials typically require sponsors to carry clinical trials liability insurance as a condition of REB approval. Tri-Council Policy Statement (TCPS2) guidance also addresses the ethical obligations of researchers and sponsors toward study participants, creating the framework within which clinical trials liability claims arise.

What clinical trials liability covers:

Adverse events experienced by trial participants attributed to the investigational product
Harm caused by study procedures that are part of the protocol
Claims arising from informed consent failures — participation without adequate understanding of risks
Costs of medical care for trial-related injuries, beyond what the trial sponsor is contractually obligated to provide
Legal defence costs for claims filed by study participants or their families

Product Liability

Product liability for life sciences companies covers bodily injury and property damage claims arising from marketed pharmaceutical products, biologics, medical devices, and health products that prove to be defective or unsafe. Given that pharmaceutical and medical device products are used by patients who are already in a compromised health state, adverse outcomes can be severe, and distinguishing between the product's effect and the underlying disease is often complex and contested in litigation.

Product liability for life sciences companies has unique characteristics compared to general product liability:

Regulatory compliance defence: A product that was approved by Health Canada and used in accordance with its approved labelling typically benefits from a regulatory compliance argument in Canadian litigation, though this is not an absolute defence
Learned intermediary doctrine: In Canada, pharmaceutical manufacturers generally discharge their duty to warn by providing adequate information to prescribing physicians, who are the "learned intermediary" — the physician's decision to prescribe is an intervening act that can affect the chain of causation
Post-market surveillance obligations: Health Canada requires manufacturers to monitor and report adverse events post-approval; failure to adequately monitor and report can remove regulatory compliance protections and increase liability exposure

Professional Liability (Scientific and Regulatory Services E&O)

Life sciences companies that provide regulatory affairs consulting, pharmacovigilance services, medical writing, clinical data management, quality assurance, or biostatistics services to other companies face professional liability for the accuracy and adequacy of those services. A regulatory affairs consulting firm whose submission preparation error causes a client's NDS or ANDS to be rejected by Health Canada, or whose clinical study report contains material errors, faces a professional negligence claim for the client's resulting delays and costs.

Directors & Officers (D&O)

Life sciences D&O exposure is shaped by the sector's investment dynamics. Biotech and life sciences companies attract significant institutional and retail investment — often based on projected clinical outcomes and regulatory timelines. When clinical trials fail, regulatory approvals are delayed or denied, or commercial launches underperform expectations, investor claims alleging misrepresentation in public disclosures or fundraising documents are a predictable response. D&O insurance for life sciences companies must be sized to reflect the potential scale of securities-related investor claims.

Cyber Liability — Research Data and Patient Health Information

Life sciences companies hold two categories of highly sensitive data: proprietary research and IP data (drug formulas, trial protocols, genomic sequences, analytical data) and patient health information (from clinical trials, patient registries, and compassionate access programs). Both categories create significant cyber liability exposure. A breach of research data creates IP theft and competitive harm; a breach of patient health information creates PHIPA and PIPEDA obligations and potential patient claims.

Key Regulatory Context for Canadian Life Sciences Companies

Health Canada and the Food and Drugs Act: All pharmaceutical products, biologics, and medical devices sold in Canada are regulated by Health Canada under the Food and Drugs Act and its regulations. The regulatory pathway — New Drug Submission (NDS), Abbreviated NDS (ANDS), Medical Device Licence — creates a compliance framework that affects both product liability exposure and clinical trials liability.

REBs and TCPS2: Clinical trials in Canada must be approved by Research Ethics Boards (REBs) operating under the Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans (TCPS2). REBs typically require sponsors to carry clinical trials liability insurance as a condition of trial approval.

ICH-E6 GCP: International Conference on Harmonisation Good Clinical Practice (ICH-E6 GCP) guidelines govern the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. GCP compliance is both a regulatory requirement and a factor in assessing professional liability for CROs and sponsors.

Frequently Asked Questions About Life Sciences & Biotech Insurance in Ontario

What insurance does a biotech startup need in Canada?

A pre-clinical stage biotech startup needs at minimum: D&O to protect investors and management, CGL for laboratory and office operations, Cyber Liability for proprietary research data protection, and Professional Liability if providing services to other companies. As the company advances to human trials, Clinical Trials Liability becomes the critical addition. At commercialization, Product Liability becomes the dominant risk. The insurance program should be structured to evolve with the company's development stage.

Is clinical trials liability required for Canadian studies?

Clinical trials liability is required as a condition of approval by most Research Ethics Boards (REBs) in Canada. TCPS2 guidance establishes that sponsors have ethical obligations to provide compensation and care for trial-related injuries to participants. While TCPS2 does not explicitly mandate insurance, REBs interpret their ethical obligations as requiring sponsors to have insurance or other financial assurance in place. Health Canada's clinical trial regulations also create a regulatory framework that is most practically satisfied through clinical trials liability insurance.

Does product liability cover FDA-approved drugs sold in Canada?

Product liability insurance responds to claims arising from products sold in Canada regardless of where they were approved. A drug approved by the FDA and also authorized by Health Canada for sale in Canada — either through a New Drug Submission or through a regulatory reliance pathway — creates Canadian product liability exposure for any adverse events experienced by Canadian patients. Canadian product liability insurance should be in place for any product sold in Canada, independent of the originating regulatory authority.

Why Ontario Life Sciences Companies Choose Boardwalk Insurance

Boardwalk Insurance is a RIBO-registered commercial insurance broker placing life sciences and biotech insurance for Ontario pharmaceutical companies, biotech firms, medical device manufacturers, CROs, CDMOs, and diagnostics companies. We access 30+ A-rated carriers including specialist life sciences markets that understand clinical trials liability, product liability for novel therapeutics, and the development-stage insurance needs of growing life sciences companies.

Get a Free Quote | +1-416-477-9771 | sales@myboardwalk.ca